Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting. We show 1 historical shares outstanding datapoints in our AVDL shares outstanding history coverage, used to compute AVDL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AVDL market cap history over the course of time is important for investors
interested in comparing AVDL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AVDL versus a peer is one thing; comparing
AVDL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AVDL can fluctuate over the course of history.
With this page we aim to empower investors researching AVDL by allowing them to research the AVDL market cap history. |
Free AVDL Email Alerts:
Video: The Importance of Market Cap
